Relamorelin (TFA)

ArtNr	HY-19884B-25mg
Hersteller	MedChem Express
CAS-Nr.	2863659-22-5
Menge	25 mg
Quantity options	100 mg 10 mg 25 mg 50 mg 5 mg
Kategorie	Inhibitors & Compound Libraries Small Molecules
Typ	Molecules
Specific against	other
Purity	99.81
Citations	[1]DeBoer MD, et, al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007 Jun;148(6):3004-12.\|[2]Fischer K, et, al. The Pentapeptide RM-131 Promotes Food Intake and Adiposity in Wildtype Mice but Not in Mice Lacking the Ghrelin Receptor. Front Nutr. 2015 Jan 12;1:31.\|[3]Zatorski H, et, al. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease. J Physiol Pharmacol. 2017 Dec;68(6):797-805.\|[4]Matthew Heckroth, et al. Nausea and Vomiting in 2021: A Comprehensive Update. J Clin Gastroenterol. 2021 Apr 1;55(4):279-299.\|[5]Victor Chedid, et al. Relamorelin for the treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2017 Oct;26(10):1189-1197.
Smiles	NC(C1(NC([C@@H](NC([C@H](NC([C@H](NC(C2CCNCC2)=O)CC3=CSC4=CC=CC=C34)=O)CC5=CNC6=CC=CC=C56)=O)CC7=CC=CC=C7)=O)CCNCC1)=O.OC(C(F)(F)F)=O
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	RM-131 (TFA),BIM-28131 (TFA)
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Type	Peptides
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Targets	GHSR
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Molecular Weight	905.00
Product Description	Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research[1][2][3][4][5].
Manufacturer - Research Area	Metabolic Disease
Solubility	H2O: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein
Clinical information	Phase 3

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-19884B-25mg-safety-datasheet.pdf